or
forgot password

A Phase 1, Open-label, Dose-Escalation Study Of The Safety And Pharmacokinetics Of SNX-5422 Mesylate In Subjects With Refractory Hematological Malignancies


Phase 1
18 Years
N/A
Not Enrolling
Both
Hematologic Neoplasms

Thank you

Trial Information

A Phase 1, Open-label, Dose-Escalation Study Of The Safety And Pharmacokinetics Of SNX-5422 Mesylate In Subjects With Refractory Hematological Malignancies


Inclusion Criteria:



- >18 years old

- Karnofsky performance status > 60

- confirmed hematological malignancy

- refractory to available therapy or for which no therapy is available

- adequate hepatic, renal and hematological function

Exclusion Criteria:

- CNS malignancy

- at risk for prolonged QT interval

- significant GI/liver disease

- other serious concurrent illness or medical condition

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

adverse events and other safety assessments

Outcome Time Frame:

continuous

Safety Issue:

Yes

Principal Investigator

Pfizer CT.gov Call Center

Investigator Role:

Study Director

Investigator Affiliation:

Pfizer

Authority:

United States: Food and Drug Administration

Study ID:

B1311002

NCT ID:

NCT00595686

Start Date:

January 2008

Completion Date:

May 2010

Related Keywords:

  • Hematologic Neoplasms
  • Hematologic Malignancies Hsp90 Hematologic Malignancy
  • Neoplasms
  • Hematologic Neoplasms

Name

Location
Pfizer Investigational Site Atlanta, Georgia  30342
Pfizer Investigational Site Asheville, North Carolina  28801
Pfizer Investigational Site Kingston, Pennsylvania  18704-5535
Pfizer Investigational Site Bristol, Tennessee  37620